&w=3840&q=100)
Star Health Insurance Q1 results: Profit falls 18% to ₹263 crore
The standalone health insurer posted a net profit of ₹319 crore during the April-June period of 2024-25.
The company's total income during the June quarter rose to ₹4,116 crore against₹ 3,692 crore in the year-ago period, Star Health said in a regulatory filing.
Gross written premium increased to₹ 3,605 crore during the quarter under review compared to ₹3,476 crore in the same period a year ago.
Last week, Insurance Regulatory and Development Authority of India imposed a penalty of ₹3.39 crore and issued a warning to Star Health and Allied Insurance Company for violations under Irdai Information & Cyber Security Guidelines, 2023.
The standalone insurer was in the spotlight last year after it came under a cyberattack in which personal data of customers got breached.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
a day ago
- Mint
Goldman Sachs, Motilal Oswal, others give ‘buy' rating to THIS mutual fund, FIIs' favourite stock
Global brokerage giant Goldman Sachs, along with Motilal Oswal and Yes Securities, recommends buying the shares of mutual funds and foreign investors-backed insurance firms Star Health and Allied Insurance Company Ltd. In its latest report, Goldman Sachs highlighted that it expects a 17.2% upside for the Star Health shares, citing the 4% YoY growth in its gross written premium (GWP) due to the company's combination of value and volumes in the April-June quarter. 'We lower our FY26-28E EPS estimates by up to 18% to factor in Q1 results, relatively gradual combined ratio improvement and revised outlook for the business over the medium term, and we maintain our 'Buy' rating on the stock,' said Goldman, highlighting that there remains room for improvement of the loss ratio trends hereon. Motilal Oswal, in its report, cited the 12% YoY rise in the net interest premiums of Star Health to ₹ 3,940 crore in the first quarter of FY2025-26. 'STARHEAL's pricing actions, underwriting strategy, and reducing pressure from claim frequency and severity will drive an improvement in the company's loss ratio trajectory in the coming quarters,' said Motilal Oswal, targeting an upside of 16% for the stock. Yes Securities expects the shares of the private insurance company to rise in the upcoming months. The brokerage firm also said that the second-quarter claims are expected to be higher, but the price hikes taken earlier will also play out in the upcoming quarter for the insurance company. 'The company has taken price corrections (hikes), altered underwriting strategies, recalibrated business and also exited some, all of which will flow through over a period of time, leading to improvement in loss ratio,' they said in the stock report. Loss ratio is the equation between the total premiums earned and actual losses incurred over a given period of time. Foreign Investors, including Foreign Direct Investments (FDIs), Foreign Portfolio Investors (FPIs), and other Foreign Institutional Investors (FIIs), hold a total of 13.76% stake in Star Health, as per the official public shareholding data. Massachusetts Institute of Technology, with a 1.64% stake, Mio Star, with 1.14%, Government Pension Fund Global, with 2.38%, and Theleme India Master Fund Ltd, with 1.53%, were among the prominent foreign investors. Other foreign stakeholders were FDIs at 3.06%, FPIs at 10.49% and 0.20%, as per the official data. ICICI Prudential Banking and Financial Services, HDFC Mutual Fund, and SBI Mutual Fund are the mutual funds that currently hold stake in the company. Goldman Sachs' Target: ₹ 500 (17.2% in a 12-month period); Buy at CMP or ₹ 426.70. Motilal Oswal Target: ₹ 520 (16% upside); Buy at CMP or ₹ 448. Yes Securities Target: ₹ 540; Buy at CMP. Star Health and Allied Insurance Company shares closed 0.76% lower at ₹ 444.50 after Thursday's stock market session, compared to ₹ 447.90 at the previous stock market session. The private sector insurer's shares have lost 50.92% since it was listed on the Indian stock market in December 2021. In the last one-year period, Star Health shares have dropped 26.57%. On a year-to-date (YTD) basis, the stock has lost 7.54% in 2025. However, the company shares have gained 5.29% in the last one-month period and are trading 4.17% higher in the last five market sessions on the Indian markets. Star Health's share price hit its 52-week high level at ₹ 647.65 on 9 September 2024, while the 52-week low level was at ₹ 330.05 on 7 April 2025, according to the data collected from the BSE website. The company's market capitalisation (M-Cap) stood at ₹ 26,179.66 crore as of the stock market close on Thursday, 31 July 2025. Read all stories by Anubhav Mukherjee Disclaimer: This story is for educational purposes only. The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Mint
2 days ago
- Mint
Nagaraj Shetti suggests Alkyl Amines, Star Health shares to buy in the short term; do you own?
Stock market today: Indian stock markets reduced their initial declines on Thursday as investors perceived the US threat of a 25% tariff and unspecified penalties, set to take effect on August 1, more as a bargaining strategy than a definitive action. As of 11:40 IST, the Nifty 50 was down 0.26% at 24,791.45 points, while the BSE Sensex fell 0.28% to 81,259.37. Both indices had dropped approximately 0.9% during early trading. Following the tariff announcement, President Donald Trump indicated that the US is still in trade negotiations with India. The proposed 25% tariff on Indian imports, along with a penalty related to energy and defense agreements with Russia, poses a clear short-term threat to exports and GDP growth, according to three analysts. As per Nagaraj Shetti from HDFC Securities, any additional decline in the Nifty 50 may encounter significant support between the 24,600 and 24,500 levels in the upcoming sessions. Shetti recommends two stocks to buy in the short-term. Here's what Shetti says about the overall market. After showing a narrow range movement on Wednesday, Nifty 50 slipped into sharp weakness on Thursday on the backdrop of US President Trump's announcement of 25% tariff and penalty on the trade deal with India and the Nifty 50 is now trading lower by 100 amidst recovery from the lows. The recent bullish pattern like bullish engulfing is still intact and Nifty 50 seems to have taken support of 24,600 for the short-term. Further weakness from here could find strong support around 24,600-24,500 levels in the coming sessions. Immediate hurdle to be watched around 24,900. Nagaraj Shetti of HDFC Securities recommends these two stocks to buy in the short-term - Alkyl Amines Chemicals Ltd, and Star Health and Allied Insurance Company Ltd. After showing a reasonable downward correction in last week, the stock price has witnessed sharp upmove so far this week. The stock price has broken above the hurdle of down sloping trend line at ₹ 2,250 and is trading higher. Volume and RSI pattern shows positive indication. The range bound movement of the last few weeks seems to be ending now for this health insurance stock. The stock is currently placed at the edge of upside breakout of 200day EMA at ₹ 448-450 levels. Bullish pattern like higher highs and lows is intact. Daily RSI shows positive indication. Disclaimer: The views and recommendations given in this article are those of individual analysts. These do not represent the views of Mint. We advise investors to check with certified experts before taking any investment decisions.
India Today
2 days ago
- India Today
Admitted by the doctor, denied by the insurer
It took a viral LinkedIn post for Star Health Insurance to approve a hospitalisation claim it had already rejected three times. But for Sumit Kumar, it was no less than mental Sumit Kumar, a Pune-based RPA business consultant, took his wife to Manipal Hospital on July 15, he wasn't expecting a battle with his insurer. Her fever had persisted for days, and after local clinics failed to help, he reached out to Star Health Insurance. 'They clearly said, 'Yes sir, you can go. We will provide cashless treatment,'' he wrote in the reassurance was enough. With Manipal Hospital confirmed as part of Star's network, Sumit and his wife headed there. The OPD was shut that afternoon, so they were directed to the emergency ward. 'The emergency doctor began treatment with IV and recommended hospitalisation citing potential symptoms of dengue and the risk of recurring fever,' Sumit said. She was admitted between 5 and 6 PM. He called Star Health again. 'Their representative assured me: 'If she is admitted for more than 24 hours, your claim will be approved.''That's not what the doctor's advice and a hospital stay of over 48 hours, Star Health denied the claim repeatedly. Their reason: 'Hospitalisation was not medically necessary/does not warrant hospitalisation.''I followed medical advice. Isn't that what a responsible husband should do?' Sumit wrote. Over the next few days, he submitted not one but three letters from the treating doctor explaining why admission was required. Star Health rejected them all.'They kept saying, 'After careful consideration, we believe hospitalisation was not required.' But who are they to decide that over the doctor?' he told 'They never explained it properly. Just copy-paste responses.' Meanwhile, as the claim remained stuck, Sumit also flagged a billing error at the hospital and eventually negotiated the final bill down to Rs 41,000, paid out of financial burden was one thing. The emotional cost was another. 'It's emotionally exhausting,' he said. 'You're worried about your wife, running around with documents, emailing, calling, begging.'He kept following up with Star Health, sending all the paperwork they asked for. The claim was rejected three he went July 26, Sumit shared his full experience on LinkedIn. 'My issue is getting resolved only because the post went viral,' he said. 'What about the others?' His post gathered traction within hours, thousands of views, comments from others with similar experiences, and a flurry of very next morning, Star Health called him. 'They apologised and said they're approving my claim now. Not the full Rs 41,000, but Rs 36,000, at least something.'He didn't submit any new documents. The only thing that changed was public final line on LinkedIn summed it up: 'We pay premiums for peace of mind, not for mental harassment.'In a statement to Star Health Insurance said, "At Star Health Insurance, all claims are reviewed by qualified medical professionals who assess the necessity of hospitalisation based on clinical evidence and established treatment protocols.""In this particular case, the initial documents submitted did not sufficiently establish the medical necessity for hospitalisation. Additionally, there were discrepancies in the hospital bill, including unusually high quantities of medication, which required further clarification," Star Health said. The insurer maintained that its team was in active communication with Sumit throughout the process and provided support for a 'seamless claim experience.'"The post-discharge and submission of a revised bill as well as the detailed indoor case papers, the claim was re-evaluated, found valid, and the reimbursement has been successfully processed," it report is part of our weekly series highlighting cases where individuals have faced undue health insurance claim rejections. If you've experienced something similar and would like to share your story, write to Ends
